254 related articles for article (PubMed ID: 37540260)
1. [Light chain amyloidosis].
Hegenbart U; Aus dem Siepen F; Schönland S
Inn Med (Heidelb); 2023 Sep; 64(9):842-847. PubMed ID: 37540260
[TBL] [Abstract][Full Text] [Related]
2. Immunoglobulin light chain amyloidosis: 2018 Update on diagnosis, prognosis, and treatment.
Gertz MA
Am J Hematol; 2018 Sep; 93(9):1169-1180. PubMed ID: 30040145
[TBL] [Abstract][Full Text] [Related]
3. Al amyloidosis.
Desport E; Bridoux F; Sirac C; Delbes S; Bender S; Fernandez B; Quellard N; Lacombe C; Goujon JM; Lavergne D; Abraham J; Touchard G; Fermand JP; Jaccard A;
Orphanet J Rare Dis; 2012 Aug; 7():54. PubMed ID: 22909024
[TBL] [Abstract][Full Text] [Related]
4. Immunoglobulin Light Chain Amyloidosis: Diagnosis and Risk Assessment.
Zanwar S; Gertz MA; Muchtar E
J Natl Compr Canc Netw; 2023 Jan; 21(1):83-90. PubMed ID: 36630897
[TBL] [Abstract][Full Text] [Related]
5. Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment.
Gertz MA
Am J Hematol; 2022 Jun; 97(6):818-829. PubMed ID: 35429180
[TBL] [Abstract][Full Text] [Related]
6. [AL amyloidosis, from diagnosis to treatment].
Villesuzanne C; Jaccard A; Nicol M
Rev Prat; 2020 Dec; 70(10):1137-1141. PubMed ID: 33739663
[TBL] [Abstract][Full Text] [Related]
7. Individualized Approach to Management of Light Chain Amyloidosis.
Palladini G; Milani P
J Natl Compr Canc Netw; 2023 Jan; 21(1):91-98. PubMed ID: 36634608
[TBL] [Abstract][Full Text] [Related]
8. Peripheral Nervous, Hepatic, and Gastrointestinal Endpoints for AL Amyloidosis Clinical Trials: Report from the Amyloidosis Forum Multi-organ System Working Group.
Mauermann ML; Clarke JO; Litchy WJ; Obici L; Lousada I; Gertz MA;
Adv Ther; 2023 Nov; 40(11):4695-4710. PubMed ID: 37658177
[TBL] [Abstract][Full Text] [Related]
9. Hepatic AL Amyloidosis without Significant Light Chain Elevation in a Patient Treated with CyBorD Plus Daratumumab.
Rybinski B; Kocoglu M
Am J Case Rep; 2021 Aug; 22():e933241. PubMed ID: 34421115
[TBL] [Abstract][Full Text] [Related]
10. [Detection of abnormal plasma cells in bone marrow contributes to the diagnosis of primary systemic light chain amyloidosis-review].
Hu Y; Zhu P
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1251-5. PubMed ID: 23114159
[TBL] [Abstract][Full Text] [Related]
11. Fibril-directed Therapies in Systemic Light Chain AL Amyloidosis.
Bhutani D; Leng S; Lentzsch S
Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):555-559. PubMed ID: 31262668
[TBL] [Abstract][Full Text] [Related]
12. Immunoglobulin light chain amyloidosis: 2024 update on diagnosis, prognosis, and treatment.
Gertz MA
Am J Hematol; 2024 Feb; 99(2):309-324. PubMed ID: 38095141
[TBL] [Abstract][Full Text] [Related]
13. Molecular Mechanism of Pathogenesis and Treatment Strategies for AL Amyloidosis.
Ikura H; Endo J; Kitakata H; Moriyama H; Sano M; Fukuda K
Int J Mol Sci; 2022 Jun; 23(11):. PubMed ID: 35683015
[TBL] [Abstract][Full Text] [Related]
14. Cardiac Amyloidosis Presenting with Pre-Excitation Syndrome, Heart Failure, and Severe Factor X Deficiency as Part of Systemic Amyloid Light-Chain (AL) Amyloidosis - A Fatal Combination.
Almasri H; Almeer A; Awouda S; Hamid O; Sardar S; Anwer Z; Ibrahim F; Soliman D; Kandathil Y; Abu-Tineh M; Alabdul Razzak I; Alazawi SH
Am J Case Rep; 2021 Aug; 22():e933398. PubMed ID: 34413281
[TBL] [Abstract][Full Text] [Related]
15. [Fibril-forming proteins: the amyloidosis. New hopes for a disease that cardiologists must know].
Arbustini E; Gavazzi A; Merlini G
Ital Heart J Suppl; 2002 Jun; 3(6):590-7. PubMed ID: 12116807
[TBL] [Abstract][Full Text] [Related]
16. Identification of clonal immunoglobulin λ light-chain gene rearrangements in AL amyloidosis using next-generation sequencing.
Kimura K; Tsukamoto S; Miyazaki K; Kawajiri-Manako C; Ishii A; Rahmutulla B; Fukuyo M; Oshima-Hasegawa N; Mitsukawa S; Takeda Y; Mimura N; Takeuchi M; Ohwada C; Iseki T; Matsusaka K; Sanada M; Yokote K; Kaneda A; Ishida T; Suzuki K; Nakaseko C; Sakaida E
Exp Hematol; 2021 Sep; 101-102():34-41.e4. PubMed ID: 34411686
[TBL] [Abstract][Full Text] [Related]
17. Novel challenges in the management of immunoglobulin light chain amyloidosis: from the bench to the bedside.
Basset M; Nuvolone M; Palladini G; Merlini G
Expert Rev Hematol; 2020 Sep; 13(9):1003-1015. PubMed ID: 32721177
[TBL] [Abstract][Full Text] [Related]
18. Muscle involvement with pseudohypertrophy in systemic light chain amyloidosis: Case report.
Draghici M; Jercan A; Badelita SN; Irimia RM; Bastian AE; Dobrea C; Popescu M; Coriu D
Medicine (Baltimore); 2021 Dec; 100(51):e28267. PubMed ID: 34941106
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis and management of systemic light chain AL amyloidosis.
Bhutani D; Lentzsch S
Pharmacol Ther; 2020 Oct; 214():107612. PubMed ID: 32562825
[TBL] [Abstract][Full Text] [Related]
20. Supportive Care in AL Amyloidosis.
Cibeira MT; Ortiz-Pérez JT; Quintana LF; Fernádez de Larrea C; Tovar N; Bladé J
Acta Haematol; 2020; 143(4):335-342. PubMed ID: 32235118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
